The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of ATM mutation and unmutated IGHV status with shorter time to first treatment (TTFT): An analysis of multigene mutation profiling and standard prognostic clinical markers in 384 treatment-naive (TN) chronic lymphocytic leukemia (CLL).
 
Boyu Hu
No Relationships to Disclose
 
Keyur Patel
No Relationships to Disclose
 
Hsiang-Chun Chen
No Relationships to Disclose
 
Xuemei Wang
No Relationships to Disclose
 
Rajyalakshmi Luthra
No Relationships to Disclose
 
Mark Routbort
No Relationships to Disclose
 
Rashmi Kanagal-Shamanna
No Relationships to Disclose
 
L Jeffrey Medeiros
No Relationships to Disclose
 
Cameron C. Yin
No Relationships to Disclose
 
Zhuang Zuo
No Relationships to Disclose
 
Chi Ok
No Relationships to Disclose
 
Sanam Loghavi
Consulting or Advisory Role - Seagen
 
Philip A. Thompson
Honoraria - Pharmacyclics
 
Michael J. Keating
No Relationships to Disclose
 
Jan Andreas Burger
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Gilead Sciences; Infinity Pharmaceuticals; Janssen; Pharmacyclics; Pharmacyclics; Pharmacyclics
Research Funding - Celgene (Inst); Gilead Sciences (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); TG Therapeutics (Inst)
 
Nitin Jain
Honoraria - Adaptive Biotechnologies; ADC Therapeutics; Novartis; Novimmune; Pfizer; Pharmacyclics; SERVIER
Consulting or Advisory Role - Adaptive Biotechnologies; ADC Therapeutics; Novartis; Novimmune; Pfizer; Pharmacyclics; SERVIER
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Pfizer (Inst); Pharmacyclics (Inst); Seagen (Inst); SERVIER (Inst)
 
Alessandra Ferrajoli
No Relationships to Disclose
 
Prithviraj Bose
Honoraria - Incyte
Consulting or Advisory Role - Incyte
Research Funding - Celgene
Travel, Accommodations, Expenses - Incyte
 
Zeev Estrov
No Relationships to Disclose
 
William G. Wierda
Consulting or Advisory Role - Abbvie; Celgene; Emergent BioSolutions; Genentech/Roche; Genzyme; Gilead Sciences; GlaxoSmithKline/Novartis; Merck; Pharmacyclics; Sanofi
Research Funding - Abbvie; Acerta Pharma; Emergent BioSolutions; Genentech; Gilead Sciences; GlaxoSmithKline/Novartis; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Pharmacyclics